Canadian Cancer Trials Group Bulletins


Highlighted Trial -- MAC.13

The current edition of the NCI Bulletin includes an item discussing Canadian Cancer Trials Group MAC.13 -- Adjuvant, Lapatinib and/or Trastuzumab Treatment Optimization Study - A Randomized, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and their Combination in Patients
with HER2/ERBB2 Positive Primary Breast Cancer (ALLTO) -- an international phase III clinical trial that aims to define the optimal treatment for early stage HER2-positive breast cancer.

The goal of MAC.13 is to optimize adjuvant anti-HER2 therapy in patients with early stage HER2-positive breast cancer. Translational research goals include enhancing our understanding of the biology of HER2-positive disease and identifying molecular markers of sensitivity and/or resistance to trastuzumab and lapatinib.

To read the article, use this link ...

To visit the trial website, use this link ...